American Society of Hirudotherapy

Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis

Case report published in Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical TrialsSafety & Infection ControlOng A et al. · Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011

Abstract

Tumor necrosis factor α (TNF-α) is a proinflammatory cytokine with pleiotropic effects. Currently, TNF-α inhibitors are approved by the Food and Drug Administration for a number of diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. We report a patient with seropositive rheumatoid arthritis with concurrent primary myelofibrosis, who had transfusion-dependent anemia and moderate thrombocytopenia that reversed during treatment with adalimumab. Rheumatoid arthritis and myeloproliferative disorder or myelodysplastic disorder often coexist, and treatment with standard immunosuppressants becomes complex. This report adds to the accumulating evidence of the safety of TNF-α inhibitors when primary myelofibrosis is present and generates discussion for further exploration of the potential therapeutic benefit of TNF-α inhibitors in cytopenias associated with primary myelofibrosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAdalimumabAnemiaAntibodies, Monoclonal, HumanizedArthritis, RheumatoidBlood TransfusionComorbidityHumansMaleMiddle AgedPrimary MyelofibrosisTreatment OutcomeTumor Necrosis Factor-alpha

Summary

Tumor necrosis factor (TNF-) is a proinflammatory cytokine with pleiotropic effects.

Why This Matters for Hirudotherapy

This case report describes a patient with concurrent seropositive rheumatoid arthritis and primary myelofibrosis whose transfusion-dependent anemia and moderate thrombocytopenia reversed during treatment with adalimumab, a tumor necrosis factor-alpha (TNF-α) inhibitor. The report adds to accumulating evidence regarding the safety of TNF-α inhibitors when primary myelofibrosis is present and generates discussion about their potential therapeutic benefit for cytopenias associated with the condition. The abstract provides no data on leeches, hirudotherapy, hirudin, or any components of the leech secretome, nor does it address anticoagulation or related therapeutic mechanisms. Therefore, this article has no apparent relevance to the American Society of Hirudotherapy based on its abstract.

Citation

Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis

Ong A et al. · Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.